Ultrasound Tissue Characterization to Diagnose Prostate Cancer
By MedImaging International staff writers
Posted on 25 Aug 2010
New innovative and proprietary tissue characterization technology has been designed to differentiate, characterize, and visualize solid organ tissue types based on the analysis of backscattered ultrasound. It was designed to support physicians in diagnosis and treatment decisions. Posted on 25 Aug 2010
Advanced Medical Diagnostics SA (AMD; Waterloo, Belgium), a privately held company focused on providing innovative computer-aided solutions (HistoScanning) that can improve the diagnostic interpretation of ultrasound scans, announced that it has appointed BK Medical UK, Ltd. as sole agent for Prostate HistoScanning in the United Kingdom.
Prostate HistoScanning, available in Europe, may support the diagnosis and management of prostate cancer. HistoScanning products for breast, thyroid, and ovaries are in development. Advanced Medical Diagnostics SA and BK Medical UK, Ltd. (Herlev; www.bkmed.com) have been working closely together since the commercial launch of Prostate HistoScanning in November 2008. These systems have been placed in four major teaching hospitals in the United Kingdom, most recently at Guys Hospital and Charing Cross Hospital in London.
As agents, BK Medical Limited will be responsible for the day-to-day management of sales and for providing service support for UK customers. Over the last 18 months, BK has been instrumental in placing over 20 Prostate HistoScanning systems alongside the BK Pro Focus and Pro Focus UltraView ultrasound systems in leading urology departments across Europe.
Toby Hamblin, VP sales of AMD, commented, "BK Medical, with its strong base in ultrasound urology in the UK, is very well placed to help us realize the full potential of Prostate HistoScanning and to provide the NHS and private clinics alike with the service and support that they, and this exciting new technology, deserve. We are very pleased to have the support of BK Medical in this important market.”
HistoScanning has not yet received market clearance by the U.S. Food and Drug Administration for commercial use in the United States.
Related Links:
Advanced Medical Diagnostics
BK Medical UK